February 26, 2026
Gilead Sciences buys Arcellx for $7.8B, doubling down on CAR-T oncology strategy
Gilead Sciences has agreed to acquire cancer therapy developer Arcellx Inc. in a transaction valued at up to $7.8 billion, deepening its footprint in cell therapy for blood cancers